Author

Masako Monika Kaufmann

University of FreiburgORCID 0000-0001-6152-6047Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Approach:contrastive learning· 1 Approach:deep learning· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1

Frequent Co-Authors

Toni CathomeniD· 2 shared Abdolreza Nazari· 1 shared Alexander MitrofanoviD· 1 shared Anamika Giri· 1 shared Andrea Sánchez PeñaiD· 1 shared Andy Roemhild· 1 shared Ashley M. JacobiiD· 1 shared C. Beltran-Mestres· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Toni CathomenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsbioRxivPreprintOct 11, 2026

CRISCross: Integration of Epigenetic Information for Deep-Learning-Based Prediction of CRISPR-Cas9 Off-Targets Across Cell Types

William Jobson Pargeter, Dominik Rabsch, Masako Monika Kaufmann…·Rolf Backofen

CRISCross improves CRISPR-Cas9 off-target prediction by integrating epigenetic features with sequence data across cell types, showing better performance than sequence-only models.

DOI 10.64898/2026.10.09.757843

DNA methylationChIP-seq

𝕏 PostBluesky

ImmunologyMolecular Therapy AdvancesPeer-reviewedApr 9, 2026

Clinical development of gene edited tacrolimus-resistant Treg (FKBP12KO-Treg) to enable simultaneous immunosuppression and support of immune regulation

Ghazaleh Zarrinrad, Lisa-Marie Burkhardt, C. Beltran-Mestres…·Leila Amini

This paper develops gene-edited tacrolimus-resistant Treg cells (FKBP12KO-Treg) for clinical use in transplant recipients, showing they maintain immunoregulatory function while resisting tacrolimus.

2 citationstop 5%

humanflow cytometry

𝕏 PostBluesky